LLY - Eli Lilly and Company
NYSE
->
Healthcare
->
Drug Manufacturers—General
Indianapolis,
United States
Type: Equity
LLY price evolution
LLY
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3223.6 | $2460.2 | $2818.6 | |
| Short term investments | $140.4 | $126.1 | $109.1 | |
| Net receivables | $12051.7 | $13079 | $10013.5 | $11336.2 |
| Inventory | $7459.8 | $6481.5 | $6101.8 | $5772.8 |
| Total current assets | $31415.1 | $30204.3 | $25188.8 | $25727 |
| Long term investments | $2877.6 | $3086.9 | $3052.2 | |
| Property, plant & equipment | $16171.8 | $14829.4 | $13624 | $12913.6 |
| Goodwill & intangible assets | $12404.3 | $11701.8 | $11846.3 | |
| Total noncurrent assets | $41670.5 | $38754.7 | $38279.3 | |
| Total investments | $3018 | $3213 | $3161.3 | |
| Total assets | $75606.9 | $71874.8 | $63943.5 | $64006.3 |
| Current liabilities | ||||
| Accounts payable | $2886.5 | $2924.8 | $2473.7 | $2598.8 |
| Deferred revenue | ||||
| Short long term debt | $5161.6 | $1651.5 | $6904.5 | |
| Total current liabilities | $24674.1 | $27121.2 | $18598.1 | $27293.2 |
| Long term debt | $29045.4 | $23730.4 | $24559.9 | $18320.8 |
| Total noncurrent liabilities | $31118.1 | $32448 | $25849.4 | |
| Total debt | $28892 | $26211.4 | $25225.3 | |
| Total liabilities | $61366.9 | $58312.8 | $51131.3 | $53142.6 |
| Shareholders' equity | ||||
| Retained earnings | $13627.2 | $13178 | $12553.9 | $10312.3 |
| Other shareholder equity | -$4258.1 | -$4345.9 | -$4268.6 | -$4327 |
| Total shareholder equity | $13562 | $12812.2 | $10771.9 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2818.6 | $2067 | $3818.5 | $3657.1 |
| Short term investments | $109.1 | $144.8 | $90.1 | $24.2 |
| Net receivables | $11336.2 | $8558.9 | $8127.2 | $6929 |
| Inventory | $5772.8 | $4309.7 | $3886 | $3980.3 |
| Total current assets | $25727 | $18034.5 | $18452.4 | $17462.1 |
| Long term investments | $3052.2 | $2901.8 | $3212.6 | $2966.8 |
| Property, plant & equipment | $12913.6 | $10144 | $8985.1 | $8681.9 |
| Goodwill & intangible assets | $11846.3 | $11279.6 | $11583.9 | $11216.5 |
| Total noncurrent assets | $38279.3 | $31455.3 | $30353.6 | $29171 |
| Total investments | $3161.3 | $3046.6 | $3302.7 | $2991 |
| Total assets | $64006.3 | $49489.8 | $48806 | $46633.1 |
| Current liabilities | ||||
| Accounts payable | $2598.8 | $1930.6 | $1670.6 | $1606.7 |
| Deferred revenue | ||||
| Short long term debt | $6904.5 | $1501.1 | $1538.3 | $8.7 |
| Total current liabilities | $27293.2 | $17138.2 | $15052.7 | $12481.6 |
| Long term debt | $18320.8 | $14737.5 | $15346.4 | $16586.6 |
| Total noncurrent liabilities | $25849.4 | $21576.2 | $24598.5 | $28326.3 |
| Total debt | $25225.3 | $16238.6 | $16884.7 | $16595.3 |
| Total liabilities | $53142.6 | $38840 | $39651.2 | $40807.9 |
| Shareholders' equity | ||||
| Retained earnings | $10312.3 | $10042.6 | $8958.5 | $7830.2 |
| Other shareholder equity | -$4327 | -$6820.7 | -$4343.1 | -$6496.4 |
| Total shareholder equity | $10771.9 | $10649.8 | $8979.2 | $5641.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11439.1 | $11302.8 | $8768 | $9353.4 |
| Cost of revenue | $2170.2 | $1673.5 | ||
| Gross Profit | $9268.3 | $9132.6 | $7094.5 | $7565.4 |
| Operating activities | ||||
| Research & development | $2711.2 | $2522.8 | ||
| Selling, general & administrative | $2117.3 | $1952.2 | ||
| Total operating expenses | $4833.9 | $5615.4 | $4558.4 | $4487.3 |
| Operating income | $3517.2 | $2536.1 | ||
| Income from continuing operations | ||||
| EBIT | $3517.2 | $2536.1 | ||
| Income tax expense | $618.1 | $550.2 | $293.2 | $319.2 |
| Interest expense | -$32.5 | -$93.7 | ||
| Net income | ||||
| Net income | $970.3 | $2967 | $2242.9 | $2189.6 |
| Income (for common shares) | $2967 | $2242.9 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $34124.1 | $28541.4 | $24539.8 | |
| Cost of revenue | $6629.8 | $5483.3 | ||
| Gross Profit | $27041.9 | $21911.6 | $19056.5 | |
| Operating activities | ||||
| Research & development | $7190.8 | $6085.7 | ||
| Selling, general & administrative | $6440.4 | $6121.2 | ||
| Total operating expenses | $16716.5 | $15105.2 | $11826.6 | |
| Operating income | $6806.4 | $7229.9 | ||
| Income from continuing operations | ||||
| EBIT | $6806.4 | $7229.9 | ||
| Income tax expense | $1314.2 | $561.6 | $1036.2 | |
| Interest expense | -$312.3 | |||
| Net income | ||||
| Net income | $5240.4 | $6244.8 | $6193.7 | |
| Income (for common shares) | $6244.8 | $6193.7 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $2967 | $2242.9 | $2189.7 | |
| Operating activities | ||||
| Depreciation | $414.4 | $400.6 | $387.7 | |
| Business acquisitions & disposals | -$947.7 | -$1044.3 | ||
| Stock-based compensation | $211.1 | $159.4 | $120.2 | |
| Total cash flows from operations | $1466.2 | $1166 | -$311.9 | |
| Investing activities | ||||
| Capital expenditures | -$1224.8 | -$986.3 | -$1070.6 | |
| Investments | $56.2 | -$29.6 | -$206.1 | |
| Total cash flows from investing | -$7381 | -$2198.7 | -$1177.6 | -$2924.3 |
| Financing activities | ||||
| Dividends paid | -$3512.1 | -$1172.4 | -$1169.2 | -$1018.1 |
| Sale and purchase of stock | ||||
| Net borrowings | $2735.9 | $1247.7 | $4594.4 | |
| Total cash flows from financing | $1455.5 | $1555.5 | -$311.3 | $3544.7 |
| Effect of exchange rate | $131.8 | -$59.6 | -$35.5 | $129.3 |
| Change in cash and equivalents | $550.4 | $763.4 | -$358.4 | $437.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5240.4 | $6244.8 | $5581.7 | $6193.7 |
| Operating activities | ||||
| Depreciation | $1527.3 | $1522.5 | $1547.6 | $1323.9 |
| Business acquisitions & disposals | -$1044.3 | -$327.2 | -$747.4 | -$849.3 |
| Stock-based compensation | $628.5 | $371.1 | $342.8 | $308.1 |
| Total cash flows from operations | $4240.1 | $7084.4 | $7260.7 | $6499.6 |
| Investing activities | ||||
| Capital expenditures | -$3447.6 | -$1854.3 | -$1309.8 | -$1387.9 |
| Investments | -$128.7 | -$244 | -$166 | $516.7 |
| Total cash flows from investing | -$7152.7 | -$3261.6 | -$2762.3 | -$2258.9 |
| Financing activities | ||||
| Dividends paid | -$4069.3 | -$3535.8 | -$3086.8 | -$2687.1 |
| Sale and purchase of stock | -$750 | -$1500 | -$1250 | -$500 |
| Net borrowings | $8649.9 | -$62 | $501.4 | $291.6 |
| Total cash flows from financing | $3495.6 | -$5406.7 | -$4131.3 | -$3137.1 |
| Effect of exchange rate | $168.6 | -$167.6 | -$205.7 | $216 |
| Change in cash and equivalents | $751.6 | -$1751.5 | $161.4 | $1319.6 |
News
Fundamentals
| Market cap | $759.79B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 949.85M |
| Revenue | $40.86B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $8.37B |
| Revenue Q/Q | 20.43% |
| Revenue Y/Y | 27.41% |
| P/E ratio | 90.78 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 18.59 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $8.81 |
|---|---|
| ROA | 12.16% |
| ROE | N/A |
| Debt/Equity | 4.93 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.27 |
| Quick ratio | 0.97 |